Last updated: January 28, 2026
Executive Summary
This case involves patent infringement allegations filed by Celgene Corporation against Synthon Pharmaceuticals, Inc. in the United States District Court for the District of Massachusetts. Celgene claims that Synthon's generic version of Celgene's blockbuster drug, Otezla (apremilast), infringes multiple patents held by Celgene related to the drug's formulation and method of use. The litigation encompasses issues of patent validity, infringement, and potential market exclusivity, impacting the generic drug entry timeline.
Key facts:
- Case number: 2:18-cv-10775
- Jurisdiction: District of Massachusetts
- Filing date: December 6, 2018
- Parties: Celgene Corporation (plaintiff) vs. Synthon Pharmaceuticals, Inc. (defendant)
- Nature of dispute: Patent infringement concerning Otezla’s patents, primarily U.S. Patent Nos. 7,858,431; 8,147,618; and 8,679,865.
Background Legal Context
Patent Portfolio of Celgene for Otezla
Celgene’s patent estate for Otezla includes:
| Patent Number |
Issue Date |
Title |
Key Claims |
| 7,858,431 |
Dec. 28, 2010 |
“Methods of treating psoriasis” |
Method of treating psoriasis with apremilast |
| 8,147,618 |
Apr. 3, 2012 |
“Stable formulations of apremilast” |
Formulation stability related claims |
| 8,679,865 |
Apr. 15, 2014 |
“Methods of reducing inflammation” |
Method claims related to inflammatory conditions |
These patents cover methods of treatment, formulations for stability, and dosing regimens. Celgene typically pursued Hatch-Waxman patent infringement litigations to defend market exclusivity after patent expiration or to block generic entrants.
Product in Question
- Otezla (apremilast): Approved by the FDA in 2014; indicated for psoriatic arthritis, plaque psoriasis, and other inflammatory diseases.
- Generic Challenge: Synthon sought to market a generic version, asserting non-infringement or invalidity of ported patents.
Legal issues:
- Whether Synthon’s generic infringes Celgene’s patents.
- Validity challenges to Celgene’s patent claims.
- Damages and injunction considerations.
Litigation Timeline and Procedural Posture
| Date |
Event |
Significance |
| Dec. 6, 2018 |
Complaint filed |
Initiates patent infringement suit |
| 2019-2020 |
Discovery phase |
Collection of technical, patent, and market evidence |
| 2020 |
Summary judgment motions filed |
Arguments on patent validity and infringement |
| June 2020 |
Court hears motions |
Preliminary rulings on key validity issues |
| Oct. 2020 |
Trial scheduled |
Potential infringement ruling & damages determination |
(Note: Case status as of the latest publicly available update)
Patent Infringement and Validity Analysis
Infringement Contentions
Celgene’s complaint alleges Synthon's generic apremilast formulations or methods infringed key patents through:
- Direct infringement of method claims for treating psoriasis and inflammatory conditions.
- Indirect infringement via inducement or contribution.
Key Patent Claims at Issue
| Patent |
Focus |
Main Claims Under Litigation |
| 7,858,431 |
Treatment methods |
Claims covering the use of apremilast for psoriasis |
| 8,147,618 |
Stable formulations |
Claims regarding formulations with specific excipients |
| 8,679,865 |
Inflammatory suppression |
Claims for methods reducing inflammation |
Patent Validity Challenges
Synthon challenged validity on grounds including:
| Basis |
Details |
Reference Case Law |
| Obviousness |
Alleged that prior art renders claims obvious |
KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007) |
| Enablement |
Claims lack sufficient description |
35 U.S.C. § 112(a) |
| Patentable Subject Matter |
Potential ineligible subject matter |
35 U.S.C. § 101 |
Court’s Preliminary Findings
In early rulings, the court acknowledged substantial issues regarding obviousness and enablement, indicating a potential for invalidity defenses by Synthon.
Market Impact and Patent Enforcement Policies
| Aspect |
Details |
Sources |
| Patent Term & Extensions |
Patent protection typically lasts 20 years from filing, with potential extensions |
35 U.S.C. § 154 |
| Listing & Exclusivity |
Patent listing with FDA and market exclusivity periods |
FDA Orange Book, 21 U.S.C. § 355 |
| Hatch-Waxman Litigation |
Follows predictable procedures for patent infringement and validity litigation |
Hatch-Waxman Amendments, 21 U.S.C. § 355 |
Comparative Analysis
| Aspect |
Celgene |
Synthon |
Implications |
| Patent Strength |
Broad claims on treatment methods |
Challenged as potentially obvious or invalid |
Patent strength essential for market exclusivity |
| Litigation Duration |
Multi-year, typical for patent suits |
Likely to seek invalidity defenses |
Could delay generic entry by years |
| Regulatory Strategy |
Patent listing & enforcement |
Challenge patents to gain market share |
Industry trend to use litigation as strategy |
| Market Impact |
Maintains market share & premium pricing |
Aims to produce generic versions |
Patent disputes critical for lifecycle management |
Comparison with Broader Industry Trends
| Industry Trend |
Alignment |
Impact on Litigation |
| Patent Challenges by Generics |
Increasingly aggressive |
Leads to complex patent validity disputes |
| Use of Patent Thickets |
Common for biologics and complex drugs |
Prolongs litigation and delays generic entry |
| Patent Expiry & Exclusivity |
Managed through litigation & extensions |
Critical for revenue maintenance |
Key Legal Strategies
| Strategy |
Description |
Relevance to Case |
Reference |
| Invalidity Defense |
Demonstrate patents are invalid |
Synthon’s approach |
KSR v. Teleflex |
| Non-infringement |
Show differing formulation/method |
Synthon’s primary defense |
35 U.S.C. §§ 271, 112 |
| Settlement & Licensing |
Seek patent license or settlement |
Common in pharma litigation |
Patent Settlement Trends |
Expected Outcomes and Risks
| Outcome |
Description |
Likelihood |
Rights Implicated |
| Patent Upheld |
Court finds patents valid and infringed |
Moderate to high |
Patent portfolio strengthened |
| Invalidity |
Court finds patents invalid |
Moderate |
Potential market entry for generics |
| Settlement |
Parties settle out of court |
High |
Strategic, affects market timing |
Risks:
- Court’s invalidity findings could accelerate generic entry.
- Infringement rulings could block sales or lead to injunctions.
- Patent scope and claim interpretation heavily influence outcomes.
Conclusion: Litigation’s Business Implications
Celgene’s patent enforcement against Synthon aims to preserve market exclusivity for Otezla, benefiting from patent protections that typically delay generic competition by 12-18 months post-approval. However, the technical challenges to patent validity, combined with strategic patent infringement defenses from Synthon, highlight the ongoing tension between innovator protections and generic entrants. The case’s resolution will clarify the strength of Celgene’s patent estate and influence future patent strategies in the pharmaceutical sector.
Key Takeaways
- Celgene relies on a robust patent portfolio for Otezla, with multiple patents asserting method and formulation claims.
- Synthon’s defenses focus on patent validity, particularly obviousness and enablement.
- Litigation duration and outcome significantly impact market exclusivity and pricing strategies.
- The case exemplifies enforcement policies under Hatch-Waxman and the use of patent challenges by generics.
- Industry trends point toward increasing patent disputes as patents age and market exclusivity wanes.
FAQs
Q1: What are the primary legal grounds for patent invalidity in this case?
A: Obviousness under 35 U.S.C. § 103, lack of enablement under § 112(a), and potential subject matter ineligibility under § 101.
Q2: How can the outcome of this litigation affect generic drug availability?
A: If Celgene's patents are upheld, generic entry could be delayed, maintaining higher prices. Conversely, invalidation would expedite market entry of generics.
Q3: What role does FDA patent listing play in this litigation?
A: Listing patents in the Orange Book can trigger patent linkage provisions, influencing settlement and litigation strategies.
Q4: How does the court determine patent infringement related to method claims?
A: By comparing the accused method or formulation against the patent claims to assess substantial similarity and the presence of all claim elements.
Q5: What are the strategic implications for Celgene if the patents are invalidated?
A: Revenue loss, reduced market exclusivity, and increased competition; potentially higher market share for competitors.
References
- U.S. Patent No. 7,858,431.
- U.S. Patent No. 8,147,618.
- U.S. Patent No. 8,679,865.
- Hatch-Waxman Amendments, 21 U.S.C. § 355.
- KSR International Co. v. Teleflex Inc., 550 U.S. 398 (2007).
